Under a strategic partnership with Alamar Biosciences, Biognosys is a provider of choice of NULISA multiplex assay services for biopharma research The NULISAseq™ CNS Disease and Inflammation panels are now available for customers as a contract research service from Biognosys' high-end proteomics facility in Europe By offering the combination of NULISA affinity-based assays and TrueDiscovery® mass spectrometrybased plasma profiling with P2 Plasma Enrichment, Biognosys offers the industry's most comprehensive ...